Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in ...
A video of Yareli Jessica Gijon having a seizure in class has gone viral reaching over 13 million views ...
Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the phase III X-TOLE2 trial showed. Over 12 weeks, adjunctive ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug ...
Research and Development (R&D) Expenses: R&D expense was $32.7 million for the first quarter of 2026, as compared to $19.6 million for the prior year period. The increase in R&D expense was primarily ...
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and ...
BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)-- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...
Xenon Pharmaceuticals Inc. ( XENE) Bank of America Global Healthcare Conference 2026 May 14, 2026 11:00 AM EDT ...
A novel cell therapy is safe and effective in patients with drug-resistant mesial temporal lobe epilepsy and could eventually offer an alternative intervention.
Epilepsy in children is a chronic neurological condition characterised by two or more unprovoked, recurring seizures resulting from sudden, abnormal electrical activity in the brain, affecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results